The results from our novel study aim to help address relevant unmet needs for clinical data in HER2-negative breast cancer patients in terms of the HER2-null, HER2-ultralow, and HER2-low subgroups and may lead to new therapeutic approaches or the development of new diagnostics in this field. This evidence concerns the gene ERBB2 and breast cancer.